Stephen K. Brannan - Mar 9, 2023 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role: Chief Medical Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol: KRTX
Transactions as of: Mar 9, 2023
Transactions value $: -$920,300
Form type: 4
Date filed: 3/9/2023, 04:12 PM
Previous filing: Feb 13, 2023
Next filing: Apr 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$27.3K	+5K	+21.14%	$5.45^*	28.7K	Mar 9, 2023	Direct
transaction	KRTX	Common Stock	Sale	-$948K	-5K	-17.45%	$189.51	23.7K	Mar 9, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-5K	-16.85%	$0.00	24.7K	Mar 9, 2023	Common Stock	5K	$5.45	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.